Femme et Homme
- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
Lenakap : This multicenter, non randomized (single arm), open, phase II study aims to evaluated the efficacy of Lenalidomide in HIV-associated kaposi disease. Patients will be followed for 48 weeks. Measurement of primary endpoint will be at 24 weeks.
Critère d'inclusion
- HIV Infection Associated Kaposi Disease